Friday, 16 October 2026European Markets

IBERSOL,SGPS And AKWEL Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - ibersol,sgps (ibs.ls) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
ibersol,sgps (ibs.ls) €6.96 11.31% 6.46%
akwel (akw.pa) €14.94 1.9% 1.9%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ibersol,sgps (ibs.ls)

11.31% forward dividend yield and 6.46% return on equity

ibersol, s.g.p.s., s.a., through its subsidiaries, operates a network of restaurants in portugal, spain, and angola. it operates restaurants under the pizza hut, pasta caffé, pans & company, ribs, frescco, santamaría, kentucky fried chicken, burger king, pans café, pizza móvil, miit, taco bell, sol, silva carvalho catering and palace catering, goto café, and other brands. the company was incorporated in 1985 and is headquartered in porto, portugal. ibersol, s.g.p.s., s.a. is a subsidiary of atps - sgps, s.a.

earnings per share

as for profitability, ibersol,sgps has a trailing twelve months eps of €0.51.

pe ratio

ibersol,sgps has a trailing twelve months price to earnings ratio of 13.65. meaning, the purchaser of the share is investing €13.65 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.46%.

sales growth

ibersol,sgps's sales growth for the current quarter is negative 23.5%.

more news about ibersol,sgps.

2. akwel (akw.pa)

1.9% forward dividend yield and 1.9% return on equity

akwel sa manufactures automotive and heavy goods vehicle components in france and internationally. it offers fluid management, mechanisms, and structural parts for electric vehicles. the company's products include body pipes, flow regulation valves, anti-return valves, pulsation dampeners or temperature, and pressure sensors; air distributors, turbo air intake and output pipes and exchangers, exhaust gas recirculation pipes, and cylinder head covers, as well as a range of solutions for cooling and combining. it also offers electronic management of hardware, software, transfer, storage, reheating, and pumping systems; and manages washer systems, including storage, pumping, transfer, and jet. the company was formerly known as mgi coutier sa and changed its name to akwel in june 2018. the company was founded in 1972 and is based in champfromier, france. akwel sa operates as a subsidiary of coutier junior company.

earnings per share

as for profitability, akwel has a trailing twelve months eps of €0.41.

pe ratio

akwel has a trailing twelve months price to earnings ratio of 36.44. meaning, the purchaser of the share is investing €36.44 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.9%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 8, 2023, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 1.9%.

volume

today's last reported volume for akwel is 1344 which is 85.13% below its average volume of 9041.

yearly top and bottom value

akwel's stock is valued at €14.94 at 02:30 est, way below its 52-week high of €19.34 and way above its 52-week low of €12.80.

more news about akwel.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com